XTR004
Phase 2Small molecule
XTR004 is one of 8 small molecule programs targeting Coronary Stenosis. It is currently in Phase 2.
1
Indications
3
Total Trials
1
Active Trials
7
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
9 competitors in Coronary Stenosis
#DrugCompanyPhaseTrials
1Victoza
Novo NordiskApproved
Bayer Aspirin
BayerApproved
Isordil
AstraZenecaApproved
Adenocard
AstellasApproved
XTR004
SSinotau Pharmaceutical Group
Phase 2
Ridaforolimus
Merck & Co.Preclinical
Definity
MMicrovascular Therapeutics, LLC
Preclinical
Optison
GGE Healthcare
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for XTR004. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- SSinotau Pharmaceutical Group